Article

Ranibizumab approved for DME in UK

Ranibizumab (Lucentis) is now available in the United Kingdom for the treatment of visual impairment due to diabetic macular edema, announced Novartis Pharmaceuticals UK Ltd.

Frimley, England-Ranibizumab (Lucentis) is now available in the United Kingdom for the treatment of visual impairment due to diabetic macular edema (DME), announced Novartis Pharmaceuticals UK Ltd.

It’s the first treatment licensed in 25 years for DME, one of the leading causes of visual impairment in the U.K. working population, according to the company.

Ranibizumab was developed by Genentech and Novartis. Genentech has the commercial rights for the drug in the United States, and Novartis has exclusive rights for it in the rest of the world.

“Ranibizumab has the potential to transform treatment for people with DME in the UK,” said Nicholas Beare, MA, MB ChB, FRCOphth, MD, consultant ophthalmologist, Royal Liverpool University Hospital, who led clinical research investigating the use of ranibizumab for DME. “For the last 25 years, laser therapy has been the standard treatment for DME, but it is not generally associated with visual improvement, whereas ranibizumab has been shown to produce a rapid and sustained improvement in vision.”

The safety profile of ranibizumab in DME is comparable with that seen in previous studies for age-related macular degeneration, according to Novartis.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.